¼¼°èÀÇ ¿ä°ü ½ºÅÙÆ® ½ÃÀå
Ureteral Stents
»óǰÄÚµå : 1784810
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 08¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 274 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,222,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,666,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¼¼°èÀÇ ¿ä°ü ½ºÅÙÆ® ½ÃÀåÀº 2030³â±îÁö 7¾ï 9,050¸¸ ´Þ·¯¿¡ À̸¦ Àü¸Á

2024³â¿¡ 5¾ï 5,830¸¸ ´Þ·¯·Î ÃßÁ¤µÇ´Â ¿ä°ü ½ºÅÙÆ® ¼¼°è ½ÃÀåÀº 2030³â¿¡´Â 7¾ï 9,050¸¸ ´Þ·¯¿¡ À̸£°í, ºÐ¼® ±â°£ÀÎ 2024-2030³â CAGRÀº 6.0%¸¦ º¸ÀÏ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. º» º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀÎ ±Ý¼Ó ¿ä°ü ½ºÅÙÆ®´Â CAGR 7.2%¸¦ ³ªÅ¸³»°í, ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 5¾ï 1,800¸¸ ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. Æú¸®¸Ó ¿ä°ü ½ºÅÙÆ® ºÐ¾ßÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£Áß CAGR 3.9%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 1¾ï 5,210¸¸ ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR 9.6%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ ¿ä°ü ½ºÅÙÆ® ½ÃÀåÀº 2024³â¿¡ 1¾ï 5,210¸¸ ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ °æÁ¦´ë±¹ÀÎ Áß±¹Àº 2024-2030³âÀÇ ºÐ¼® ±â°£¿¡ CAGR 9.6%·Î ¼ºÀåÀ» Áö¼ÓÇÏ¿©, 2030³â¿¡´Â 1¾ï 6,280¸¸ ´Þ·¯ ±Ô¸ð¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ±âŸ ÁÖ¸ñÇØ¾ß ÇÒ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£Áß CAGRÀº °¢°¢ 2.8%¿Í 5.9%¸¦ º¸ÀÏ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 3.9%¸¦ º¸ÀÏ Àü¸ÁÀÔ´Ï´Ù.

¼¼°èÀÇ ¿ä°ü ½ºÅÙÆ® ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

ºñ´¢±â°ú Áúȯ Áõ°¡°¡ ½ºÅÙÆ® ±â¹Ý ÀÎÅͺ¥¼ÇÀÇ »õ·Î¿î ½Ã´ë¸¦ À̲ø °ÍÀΰ¡?

¼¼°èÀûÀ¸·Î ºñ´¢±â°ú ÁúȯÀÇ ¹ß»ý·üÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ¿ä°ü ½ºÅÙÆ®¿¡ ´ëÇÑ ¼ö¿ä°¡ Å©°Ô Áõ°¡ÇÏ¿© Çö´ë ºñ´¢±â°ú Ä¡·á¿¡¼­ Áß¿äÇÑ µµ±¸°¡µÇ¾ú½À´Ï´Ù. ¿ä°ü ½ºÅÙÆ®´Â ¿ä°ü¿¡ »ðÀÔÇÏ¿© ¿ä°ü ¸·ÈûÀ» Á¦°ÅÇÏ°í ½ÅÀå¿¡¼­ ¹æ±¤À¸·Î ¼Òº¯ ¹èÃâÀ» ÃËÁøÇÏ¿© ¼ö¼ú ÈÄ Ä¡À¯¸¦ µ½´Â °¡´Ã°í Ç÷º¼­ºí Æ©ºêÀÔ´Ï´Ù. ½ÅÀå°á¼®(¿ä·Î°á¼®Áõ), Àü¸³¼±ºñ´ëÁõ(BPH), ÇùÂø, Á¾¾ç, ¼ö¼ú ÈÄ ºÎÁ¾ µî ÁúȯÀÇ À¯º´·üÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ¿ä°ü ½ºÅÙÆ®ÀÇ »ç¿ëÀº º´¿ø°ú ºñ´¢±â°ú Ŭ¸®´Ð¿¡¼­ Á¡Á¡ ´õ ÀÏ»óÈ­µÇ¾î °¡°í ÀÖ½À´Ï´Ù. ƯÈ÷, ºñ¸¸°ú ´ç´¢º´°ú °°Àº »ýȰ½À°ü °ü·Ã ´ë»ç¼º ÁúȯÀÌ Àü ¼¼°èÀûÀ¸·Î ±ÞÁõÇÏ´Â °ÍÀº °á¼® Çü¼º·ü Áõ°¡¿Í °ü·ÃÀÌ ÀÖÀ¸¸ç, ÀÌ´Â °£Á¢ÀûÀ¸·Î ÀϽÃÀû ¶Ç´Â °íÁ¤½Ä ½ºÅÙÆ® »ðÀÔ¼ú¿¡ ´ëÇÑ ¼ö¿ä¸¦ ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¿ä°ü°æ °Ë»ç, °æÇÇÀû ½Å°á¼® Á¦°Å¼ú(PCNL), º¹°­°æ ¼ö¼ú°ú °°Àº Àúħ½ÀÀû ¿ä·Î ³» ¼ö¼úÀÌ º¸ÆíÈ­µÊ¿¡ µû¶ó ¼ö¼ú ÈÄ ¹è¾×À» º¸ÀåÇϰí ÇÕº´ÁõÀ» ¿¹¹æÇϱâ À§ÇØ ¿ä°ü ½ºÅÙÆ®°¡ Á¡Á¡ ´õ ¸¹ÀÌ »ç¿ëµÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¿ä·Î ±â´É Àå¾Ö ¹× ¾Ç¼º Á¾¾ç¿¡ °É¸®±â ½¬¿î °í·ÉÈ­·Î ÀÎÇØ Àå±âÀûÀÎ ½ºÅÙÆ® ÁöÁö°¡ ÇÊ¿äÇÑ È¯ÀÚÃþÀÌ È®´ëµÇ°í ÀÖ½À´Ï´Ù. ºñ´¢±â °Ç°­¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁö°í Áø´Ü ±â¼úÀÌ Çâ»óµÊ¿¡ µû¶ó ´õ ¸¹Àº »ç·Ê°¡ Á¶±â¿¡ ¹ß°ßµÇ¾î Àû½Ã¿¡ ½ºÅÙÆ®¸¦ »ðÀÔ ÇÒ ¼öÀÖ´Â Èĺ¸ÀÚ°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù.

Àç·á Çõ½Å°ú ȯÀÚ Á᫐ ¼³°è°¡ ½ºÅÙÆ® ¼º´ÉÀ» ¾î¶»°Ô Çâ»ó½Ã۰í Àִ°¡?

½ºÅÙÆ® µðÀÚÀÎ, Àç·á, ÄÚÆÃÀÇ ±â¼úÀû ¹ßÀüÀº ȯÀÚ °á°ú, ³»¾à¼º, ½Ã¼ú È¿À²À» Å©°Ô Çâ»ó½ÃÄ×½À´Ï´Ù. Æú¸®¿ì·¹Åº°ú ½Ç¸®ÄÜÀ¸·Î ¸¸µé¾îÁø ±âÁ¸ÀÇ ½ºÅÙÆ®´Â »ýü ÀûÇÕ¼º, À¯¿¬¼º, µüÁö Çü¼º ¹× °¨¿°¿¡ ´ëÇÑ ÀúÇ×¼ºÀÌ ¶Ù¾î³­ Â÷¼¼´ë Àç·á·Î °­È­µÇ°Å³ª ´ëüµÇ°í ÀÖ½À´Ï´Ù. Ä£¼ö¼º ÄÚÆÃ, Ç×±ÕÃþ, ¾à¹° ¿ëÃâ ½ºÅÙÆ®´Â ½ºÅÙÆ® Àå±â »ç¿ë¿¡ µû¸¥ ÀϹÝÀûÀÎ ÇÕº´ÁõÀÎ ÀÚ±Ø, ºÒÆí°¨, ¿ä·Î°¨¿°(UTI)ÀÇ À§ÇèÀ» ÁÙÀÏ ¼ö ÀÖ¾î Àα⸦ ²ø°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, »ýºÐÇØ¼º ½ºÅÙÆ®´Â Á¦°Å ½Ã¼úÀÇ Çʿ伺À» ¾ø¾Ö°í ȯÀÚÀÇ ºÎ´ã°ú Àüü ÀÇ·á ºñ¿ëÀ» Àý°¨ÇÒ ¼ö ÀÖ¾î Àα⸦ ²ø°í ÀÖ½À´Ï´Ù. ÀÌ ½ºÅÙÆ®´Â ½Ã°£ÀÌ Áö³²¿¡ µû¶ó ÀÚ¿¬ÀûÀ¸·Î ¿ëÇØµÇ±â ¶§¹®¿¡ °á¼® ¹× ÇùÂø °ü¸® ¹× ¼ö¼ú ÈÄ È¸º¹¿¡ ´Ü±â°£ »ç¿ëÇϱ⿡ ÀÌ»óÀûÀÔ´Ï´Ù. ¶ÇÇÑ, °¢ Á¦Á¶¾÷üµéÀº Á¦°Å¿ë ½ºÆ®¸µ, ÀÚ¼®½Ä Á¦°Å ÆÁ, ÇØºÎÇÐÀûÀÎ Â÷ÀÌ¿¡ µû¶ó ¸ÂÃãÇü ±æÀÌ¿Í ¸ð¾çÀÇ ½ºÅÙÆ® µî ȯÀÚ Ä£È­ÀûÀÎ Çõ½Å¿¡ ÅõÀÚÇϰí ÀÖ½À´Ï´Ù. ¹ÙÀÌ¿À¼¾¼­¿Í ¹«¼± ¸ð´ÏÅ͸µ ±â´ÉÀ» °®Ãá ½º¸¶Æ® ½ºÅÙÆ® ÇÁ·ÎÅäŸÀÔµµ °³¹ß ÁßÀ¸·Î, ½Ç½Ã°£À¸·Î ½ºÅÙÆ®ÀÇ À§Ä¡, À¯·®, ¸·Èû °¨Áö µîÀ» ÃßÀûÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Çõ½ÅÀº ÀÓ»óÀû È¿À²¼ºÀ» ³ôÀÏ »Ó¸¸ ¾Æ´Ï¶ó Àü¹ÝÀûÀΠȯÀÚ °æÇèÀ» °³¼±ÇÏ´Â °ÍÀ¸·Î, ¼±ÅÃÀû ºñ´¢±â°ú ¼ö¼úÀÌ ¿Ü·¡·Î À̵¿ÇÏ°í Æí¾ÈÇÔ°ú ÆíÀǼº¿¡ ´ëÇÑ È¯ÀÚµéÀÇ ±â´ë°¡ ³ô¾ÆÁö´Â »óȲ¿¡¼­ ¸Å¿ì Áß¿äÇÕ´Ï´Ù.

¿Ü·¡ ºñ´¢±â°ú Ä¡·á´Â ½ºÅÙÆ® »ç¿ëÀÇ ´ÙÀ½ ´Ü°è¸¦ Çü¼ºÇÒ °ÍÀΰ¡?

¼¼°èÀûÀ¸·Î ¿Ü·¡È¯ÀÚ Ä¡·á¿Í ´çÀÏ ¼ö¼ú·ÎÀÇ ÀüȯÀº ¿ä°ü ½ºÅÙÆ® ½ÃÀåÀÇ ÀçÆí¿¡ ÀÖ¾î ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù. ºñ´¢±â°úÀû ÃÖ¼Òħ½ÀÀû °³ÀÔÀÌ ³Î¸® äÅõǸ鼭 °á¼® Á¦°Å ¹× ÇùÂø È®Àå µîÀÇ ½Ã¼úÀÌ ¿Ü·¡ ȯÀÚ È¯°æ¿¡¼­ º¸´Ù ½Å¼ÓÇÏ°í ¾ÈÀüÇÏ°Ô ÀÌ·ç¾îÁú ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. ¿ä°ü ½ºÅÙÆ®´Â ½Ã¼ú ÈÄ ÇʼöÀûÀÎ µµ±¸·Î¼­ ÀÌ·¯ÇÑ º¯È­ÀÇ ÇýÅÃÀ» Á÷Á¢ÀûÀ¸·Î ´©¸®°í ÀÖ½À´Ï´Ù. ¿Ü·¡¼ö¼ú¼¾ÅÍ(ASC)³ª µ¥ÀÌÄÉ¾î ºñ´¢±â°ú º´µ¿¿¡¼­´Â ÀÔ¿ø ½Ã¼³¿¡ ºñÇØ ºü¸£°í Àú·ÅÇÑ ºñ¿ëÀ¸·Î ½ºÅÙÆ® »ðÀÔ ¹× Á¦°Å¸¦ ÇÒ ¼ö ÀÖ´Â Àåºñ°¡ Á¡Á¡ ´õ Àß °®Ãß¾îÁö°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Ãß¼¼´Â ½Ã¼ú °Ç¼ö¸¦ Áõ°¡½Ãų »Ó¸¸ ¾Æ´Ï¶ó, »ðÀÔÀÌ ¿ëÀÌÇϰí Á¶¸³µÈ ½ºÅÙÆ® ŰƮ ¹× ÀÏȸ¿ë ±â±â¿¡ ´ëÇÑ ¼ö¿äµµ Áõ°¡½Ã۰í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ½ºÅÙÆ® ÃßÀû ½Ã½ºÅÛ°ú ¸ð¹ÙÀÏ °Ç°­ ¾ÛÀÇ µîÀåÀ¸·Î ÈÄ¼Ó Ä¡·á°¡ °£¼ÒÈ­µÇ¾î ±×µ¿¾È °£°úµÇ¾î ¿Ô´ø ÇÕº´ÁõÀÎ ½ºÅÙÆ® »ðÀÔ ¹× »ðÀÔÀ» Àؾî¹ö¸®´Â À§ÇèÀÌ °¨¼ÒÇϰí ÀÖ½À´Ï´Ù. Àåºñ Á¦Á¶¾÷ü¿Í ¿Ü·¡ ¼ö¼ú ³×Æ®¿öÅ©¿ÍÀÇ Çù·Â °ü°èÀÇ ½ÉÈ­´Â °í󸮷® ¹× ºñ¿ë Áß½ÉÀÇ È¯°æ¿¡ ¸Â´Â Á¦Ç° ¼³°è ¹× Á¦°øÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ºñ´¢±â°ú ¿Ü·¡ Áø·á·ÎÀÇ À̵¿Àº °¡Ä¡ ±â¹Ý Ä¡·á ¹× ȯÀÚ Áß½É Ä¡·á °æ·Î¿Í °°Àº ±¤¹üÀ§ÇÑ ÇコÄÉ¾î Æ®·»µå¿Íµµ ¸Â¹°·Á ÀÖÀ¸¸ç, ¿ä°ü ½ºÅÙÆ®´Â ÀÓ»óÀû Çʿ伺°ú Ä¡·á ÃÖÀûÈ­¸¦ À§ÇÑ ±âȸ·Î ÀÚ¸®¸Å±èÇϰí ÀÖ½À´Ï´Ù. ¼ö¼ú Çõ½Å°ú ȯÀÚ È帧 °ü¸® »çÀÌÀÇ ÀÌ·¯ÇÑ ÀÏÄ¡´Â ÁøÈ­ÇÏ´Â ºñ´¢±â°ú Áø·áÀÇ ÇʼöÀûÀÎ ºÎºÐÀ¸·Î¼­ ½ºÅÙÆ®ÀÇ ¿ªÇÒÀ» °­È­Çϰí ÀÖ½À´Ï´Ù.

¼¼°è ¿ä°ü ½ºÅÙÆ® ½ÃÀåÀÇ ¼ºÀåÀ» ÁÖµµÇÏ´Â ¿äÀÎÀº ¹«¾ùÀΰ¡?

¿ä°ü ½ºÅÙÆ® ½ÃÀåÀÇ ¼ºÀåÀº ÀÓ»óÀû ¼ö¿ä, Àα¸Åë°èÇÐÀû ¿äÀÎ, ±â¼ú ¹ßÀü, ÁøÈ­ÇÏ´Â Ä¡·á Á¦°ø ¸ðµ¨ÀÇ Á¶ÇÕ¿¡ ÀÇÇØ ÀÌ·ç¾îÁý´Ï´Ù. ÁÖ¿ä ÃËÁø¿äÀÎ Áß Çϳª´Â ¿ä·Î°á¼®Áõ ¹× ±âŸ Æó¼â¼º ºñ´¢±â ÁúȯÀÇ Àü ¼¼°è À¯º´·ü Áõ°¡·Î ÀϽÃÀû ¶Ç´Â ¿µ±¸ÀûÀÎ ½ºÅÙÆ® »ðÀÔÀ» ÅëÇÑ °³ÀÔÀÌ ÇÊ¿äÇÏ°Ô µÇ¾ú½À´Ï´Ù´Â Á¡ÀÔ´Ï´Ù. ÃÖ¼Òħ½À ¼ö¼ú ±â¹ýÀÇ º¸±ÞÀ¸·Î ƯÈ÷ ¿Ü·¡ ȯÀÚ ¹× ¿Ü·¡ ȯ°æ¿¡¼­ ¼ö¼ú ÈÄ ½ºÅÙÆ® »ðÀÔÀ» Áö¿øÇØ¾ß ÇÒ Çʿ伺ÀÌ ´õ¿í Ä¿Áö°í ÀÖ½À´Ï´Ù. ¾à¹° ¿ëÃ⼺ ÄÚÆÃ, »ýü Èí¼ö¼º Àç·á, ¿ª·ù ¹æÁö ¹ëºê µî ½ºÅÙÆ® ¼³°èÀÇ ¹ßÀüÀ¸·Î ½ºÅÙÆ®ÀÇ ¼º´ÉÀÌ Å©°Ô Çâ»óµÇ°í ÇÕº´Áõ ¹ß»ý·üÀÌ °¨¼ÒÇÏ¿© ½ºÅÙÆ®´Â ȯÀÚ¿Í ÀÇ·áÁø ¸ðµÎ¿¡°Ô ´õ¿í ¸Å·ÂÀûÀ¸·Î ´Ù°¡°¥ ¼ö ÀÖ½À´Ï´Ù. ƯÈ÷ ½ÅÈï±¹ ½ÃÀå¿¡¼­´Â °í·ÉÈ­°¡ ÁøÇàµÇ¸é¼­ Àå±âÀûÀÎ ½ºÅÙÆ® »ðÀÔÀÌ ÇÊ¿äÇÑ ¸¸¼º ¿ä·Î ±â´É Àå¾Ö »ç·Ê°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ½ÅÈï ½ÃÀå¿¡¼­ÀÇ ÇコÄɾî ÀÎÇÁ¶ó ±¸Ãà°ú ÀÎÁöµµ Çâ»óµµ ½Ã¼ú·ü°ú ±â±â äÅÃÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ ºñ´¢±â°ú Ä¡·á¿¡ ´ëÇÑ Á¤ºÎ ¹× ¹Î°£ ÁöºÒÀÚÀÇ Áö¿ø°ú °ø±Þ¸Á ¹× Á¦Ç° Á¢±Ù¼ºÀÇ Çõ½ÅÀÌ °áÇÕµÇ¾î ½ÃÀå ħÅõ°¡ °¡¼ÓÈ­µÇ°í ÀÖ½À´Ï´Ù. ÇöÀç ÁøÇà ÁßÀÎ °³ÀÎ ¸ÂÃãÇü ÀÇ·á Æ®·»µå´Â Á¦Á¶¾÷üµéÀÌ ÇØºÎÇÐÀûÀ¸·Î Á¶Á¤µÈ ȯÀÚº° ¼Ö·ç¼ÇÀ» Á¦°øÇϵµ·Ï À¯µµÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ÈûµéÀÌ ¼ö·ÅµÊ¿¡ µû¶ó ¿ä°ü ½ºÅÙÆ® ½ÃÀåÀº ÀÓ»óÀû È¿°ú¿Í ȯÀÚ »îÀÇ Áú Çâ»óÀ̶ó´Â µÎ °¡Áö °úÁ¦¿¡ ÈûÀÔ¾î Áö¼ÓÀûÀ¸·Î È®´ëµÉ ż¼¸¦ °®Ãß°í ÀÖ½À´Ï´Ù.

ºÎ¹®

¼ÒÀç(±Ý¼Ó ¿ä°ü ½ºÅÙÆ®, Æú¸®¸Ó ¿ä°ü ½ºÅÙÆ®);¿ëµµ(½Å°á¼®, ½ÅÀå À̽Ä, Á¾¾ç, ¿ä½Ç±Ý, ±âŸ)

Á¶»ç ´ë»ó ±â¾÷ ¿¹

AI ÅëÇÕ

Global Industry Analysts´Â À¯È¿ÇÑ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AIÅø¿¡ ÀÇÇØ ½ÃÀå Á¤º¸¿Í °æÀï Á¤º¸¸¦ º¯ÇõÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â ÀϹÝÀûÀÎ LLM³ª ¾÷°èº° SLM Äõ¸®¿¡ µû¸£´Â ´ë½Å¿¡, ºñµð¿À ±â·Ï, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ´ë·® ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî, Àü ¼¼°è Àü¹®°¡·ÎºÎÅÍ ¼öÁýÇÑ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»ç ¼ÒÀçÁö, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±âÁØÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇß½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¼öÀÍ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº Ç϶ô, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû, °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

LSH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Ureteral Stents Market to Reach US$790.5 Million by 2030

The global market for Ureteral Stents estimated at US$558.3 Million in the year 2024, is expected to reach US$790.5 Million by 2030, growing at a CAGR of 6.0% over the analysis period 2024-2030. Metallic Ureteral Stents, one of the segments analyzed in the report, is expected to record a 7.2% CAGR and reach US$518.0 Million by the end of the analysis period. Growth in the Polymer Ureteral Stents segment is estimated at 3.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$152.1 Million While China is Forecast to Grow at 9.6% CAGR

The Ureteral Stents market in the U.S. is estimated at US$152.1 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$162.8 Million by the year 2030 trailing a CAGR of 9.6% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.8% and 5.9% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.9% CAGR.

Global Ureteral Stents Market - Key Trends & Drivers Summarized

Is the Rise in Urological Disorders Driving a New Era of Stent-Based Interventions?

The growing global incidence of urological disorders is significantly increasing the demand for ureteral stents, making them a critical tool in modern urological care. Ureteral stents are thin, flexible tubes inserted into the ureters to relieve obstructions, facilitate urine drainage from the kidney to the bladder, and support healing post-surgery. With the rising prevalence of conditions such as kidney stones (urolithiasis), benign prostatic hyperplasia (BPH), strictures, tumors, and post-surgical edema, the use of ureteral stents has become increasingly routine across hospitals and urology clinics. In particular, the global upsurge in lifestyle-related metabolic disorders like obesity and diabetes is linked to higher rates of stone formation, thus indirectly fueling demand for temporary or indwelling stenting procedures. As minimally invasive endourological procedures such as ureteroscopy, percutaneous nephrolithotomy (PCNL), and laparoscopic surgeries become more common, ureteral stents are increasingly utilized to ensure post-operative drainage and prevent complications. Additionally, the aging population-which is more susceptible to urinary tract dysfunction and malignancies-is expanding the patient base requiring long-term stent support. As awareness of urinary health grows and diagnostic technologies improve, more cases are being identified earlier, creating a larger pool of candidates for timely stenting interventions.

How Are Material Innovations and Patient-Centric Designs Elevating Stent Performance?

Technological advancements in stent design, materials, and coatings are significantly improving patient outcomes, tolerability, and procedural efficiency. Traditional stents made of polyurethane or silicone are being enhanced or replaced with new-generation materials that offer superior biocompatibility, flexibility, and resistance to encrustation and infection. Hydrophilic coatings, anti-microbial layers, and drug-eluting stents are gaining popularity for their ability to reduce irritation, discomfort, and risk of urinary tract infections (UTIs)-common complications associated with long-term stent use. Moreover, biodegradable stents are gaining traction as they eliminate the need for removal procedures, reducing patient burden and overall healthcare costs. These stents naturally dissolve over time, making them ideal for short-term use and post-operative recovery in stone and stricture management. In addition, manufacturers are investing in patient-friendly innovations such as stents with extraction strings, magnetic retrieval tips, and customizable lengths and shapes tailored to anatomical variability. Smart stent prototypes equipped with biosensors and wireless monitoring capabilities are in the pipeline, enabling real-time tracking of stent position, flow rates, and obstruction detection. These innovations are not only enhancing clinical efficiency but also elevating the overall patient experience, which is crucial as elective urological procedures shift toward outpatient settings and patient expectations for comfort and convenience rise.

Is Outpatient Urological Care Shaping the Next Phase of Stent Utilization?

The global shift toward outpatient care and same-day surgical procedures is playing a pivotal role in reshaping the ureteral stents market. The widespread adoption of minimally invasive urological interventions has made procedures such as stone removal and stricture dilation faster, safer, and more suitable for outpatient environments. Ureteral stents, as an essential post-procedure tool, are benefiting directly from this shift. Ambulatory surgical centers and day-care urology units are increasingly equipped to perform stent placements and removals with rapid turnaround and lower costs compared to inpatient facilities. This trend is not only boosting procedural volumes but also driving demand for easy-to-insert, pre-assembled stent kits and single-use instrumentation. Additionally, the emergence of stent tracking systems and mobile health apps is streamlining follow-up care and reducing the risk of forgotten or retained stents-a historically overlooked complication. The growing collaboration between device manufacturers and outpatient surgical networks is facilitating the design and delivery of products tailored to high-throughput, cost-sensitive environments. The movement toward outpatient urology also intersects with broader healthcare trends such as value-based care and patient-centric treatment pathways, positioning ureteral stents as both a clinical necessity and an opportunity for care optimization. This alignment between surgical innovation and patient flow management is reinforcing the role of stents as an integral part of evolving urological practice.

What Is Driving the Growth of the Global Ureteral Stents Market?

The growth in the ureteral stents market is driven by a combination of clinical demand, demographic factors, technological progress, and evolving care delivery models. One of the primary drivers is the rising global prevalence of urolithiasis and other obstructive urological conditions, which necessitate intervention using temporary or permanent stents. The widespread adoption of minimally invasive surgical techniques has further elevated the need for supportive stenting post-procedure, especially in the context of outpatient and ambulatory settings. Advances in stent design-such as drug-eluting coatings, bioabsorbable materials, and anti-reflux valves-are significantly improving device performance and reducing complication rates, making stents more appealing to both patients and providers. The aging population, particularly in developed markets, is contributing to increased volumes of chronic urinary dysfunction cases requiring long-term stenting. Improved healthcare infrastructure and awareness in emerging markets are also boosting procedural rates and device adoption. Additionally, government and private payer support for urological care-combined with innovations in supply chain and product accessibility-are accelerating market penetration. The ongoing trend of personalized medicine is pushing manufacturers to offer anatomically tailored, patient-specific solutions. As these forces converge, the ureteral stents market is poised for continued expansion, supported by the dual imperatives of clinical efficacy and improved patient quality of life.

SCOPE OF STUDY:

The report analyzes the Ureteral Stents market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Material (Metallic Ureteral Stents, Polymer Ureteral Stents); Application (Kidney Stones, Kidney Transplantation, Tumors, Urinary Incontinence, Others)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 34 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â